Other languages Johnson & Johnson London S.E.

Equities

0R34

US4781601046

Market Closed - London S.E. Other stock markets 16:35:26 26/06/2024 BST			After market 20:53:50
148.4 ^USD	-0.47%		147.1	-0.87%

06-24	US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	RE
06-24	J&J: 50M pupils helped through 'Sight for Kids' program	CF

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	06-24
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	06-24
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06-21
Johnson & Johnson : dossier déposé dans la maladie de Crohn	06-21
Johnson & Johnson : le rachat de Proteologix est bouclé	06-21
Johnson & Johnson Completes Acquisition of Proteologix	06-21
Johnson & Johnson Completes Acquisition of Proteologix	06-21
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	06-20
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	06-20
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	06-20
J&J : lance un écosystème numérique ouvert et sécurisé	06-20
J&J : des résultats prometteurs dans la maladie de Crohn	06-20
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	06-20
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease	06-20
J&J : sollicite la FDA dans le cancer du poumon	06-17
Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer	06-17
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	06-17
J&J : résultat positif dans la maladie de Sjögren	06-17
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	06-17
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	06-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm